# US 2012/0252792 A1 · Methods and compositions for modulating rho-mediated gene transcription

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252792 A1
- Document ID: US20120252792A1
- Status: Published application
- Kind: A1
- Application number: 13/496,827
- Filed: 2010-09-17
- Published: 2012-10-04
- Earliest claimed: 2009-09-17
- Assignees: The Regents of the University of Michigan
- Inventors: Richard Neubig; Chris Evelyn; Jenny Ryu; Scott Larsen; Jessica Bell
- Web page: https://patentgrep.com/patent/US20120252792A1

## CPC

- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/4192: 1,2,3-Triazoles
- A61K 31/421: 1,3-Oxazoles, e.g. pemoline, trimethadione
- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 15/10: for impotence
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention provides methods, compositions, and kits for the inhibition of members of the Rho GTPase family. Specifically, the invention provides methods, compositions and kits for the inhibition of RhoA and/or RhoC transcriptional signalling. The invention finds use in treatment of Rho-mediated disease states (e.g., tumor metastasis, inflammation, inflammatory disease), Rho-mediated biological conditions, and in cell signaling research.

## Claims

### Claim 1

A composition comprising a compound selected from the group consisting of
wherein G1 and G2 may be independently selected from the group consisting of (C═O)NH, NH(C═O), (C═O)NHO, NH, O, NH(C═O)O, O(C═O)NH, and heteroaryl;
wherein p and q may be independently 1, 2, 3, 4, or 5;
wherein R1 and R2 may be one or more functional groups independently selected from the group consisting of halogen, CF3, OCF3, CN, O(C1-C6 alkyl), and C1-C6 alkyl;
wherein X, Y, Z are independently: (CH2)m wherein m is 0, 1, or 2 and n is 1, 2, or 3;
wherein G1 and G2 are not CONH when R1 is 3,5-bis(CF3) and R2 is 4-Cl;
wherein heteroaryl is selected from the group consisting of 1,3-thiazole and isoxazole; and
wherein T is selected from the group consisting of:

### Claim 2 (depends on 1)

The composition of claim 1, wherein said composition is selected from the group consisting of
wherein p and q may be independently 1, 2, 3, 4, or 5.

### Claim 3 (depends on 1)

The composition of claim 1 wherein said composition is in a pharmaceutically appropriate formulation for administration to a human subject.

### Claim 4 (depends on 2)

The composition of claim 2, wherein said composition is in a pharmaceutically appropriate formulation for administration to a human subject.

### Claim 5 (depends on 1)

The composition of claim 1, wherein said composition has an IC50 value for rho protein of between 1 and 50,000 nM.

### Claim 6 (depends on 5)

The composition of claim 5, wherein said rho protein is selected from the group consisting of rhoA and rhoC.

### Claim 7 (depends on 1)

The composition of claim 1, wherein said composition results in 50% or less inhibition of WST-1 metabolism in an in vitro cell when said composition is administered to said in vitro cell at a concentration of 10 μM.

### Claim 8 (depends on 1)

A method of treating a rho-mediated disease in a subject comprising administering a compound of claim 1 in a pharmaceutically appropriate formulation to said subject.

### Claim 9 (depends on 1)

A method of preventing a rho-mediated disease in a subject comprising administering a compound of claim 1 in a pharmaceutically appropriate formulation to said subject.

### Claim 10 (depends on 8)

The method of claim 8, wherein said rho-mediated disease is selected from the group consisting of cancer, inflammation, inflammatory disease, pulmonary arterial hypertension, axon regeneration following nerve damage, Raynaud's phenomenon, cerebral vascular disease, cardiovascular disease, and erectile dysfunction.

### Claim 11 (depends on 10)

The method of claim 10, wherein said cancer type is selected from the group consisting of fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, Ewing's tumor, lymphangioendotheliosarcoma, synovioma, mesothelioma, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, leukemia, polycythemia vera, lymphoma, multiple myeloma, Waldenstrom's macroglobulinemia, and heavy chain disease.

### Claim 12 (depends on 10)

The method of claim 10, wherein said inflammatory disease is selected from the group consisting of arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, degenerative arthritis, polymyalgia rheumatic, ankylosing spondylitis, reactive arthritis, gout, pseudogout, inflammatory joint disease, systemic lupus erythematosus, polymyositis, fibromyalgis, achilles tendinitis, achondroplasia, acromegalic arthropathy, adhesive capsulitis, adult onset Still's disease, anserine bursitis, avascular necrosis, Behcet's syndrome, bicipital tendinitis, Blount's disease, brucellar spondylitis, bursitis, calcaneal bursitis, calcium pyrophosphate deposition disease, crystal deposition disease, Caplan's syndrome, carpal tunnel syndrome, chondrocalcinosis, chondromalacia patellae, chronic synovitis, chronic recurrent multifocal osteomyelitis, Churg-Strauss syndrome, Cogan's syndrome, corticosteroid-induced osteoporosis, costosternal syndrome, CREST syndrome, cryoglobulinemia, degenerative joint disease, dermatomyositis, diabetic finger sclerosis, diffuse idiopathic skeletal hyperostosis, discitis, discoid lupus erythematosus, drug-induced lupus, Duchenne's muscular dystrophy, Dupuytren's contracture, Ehlers-Danlos syndrome, enteropathic arthritis, epicondylitis, erosive inflammatory osteoarthritis, exercise-induced compartment syndrome, Fabry's disease, familial Mediterranean fever, Farber's lipogranulomatosis, Felty's syndrome, Fifth's disease, flat feet, foreign body synovitis, Freiberg's disease, fungal arthritis, Gaucher's disease, giant cell arteritis, gonococcal arthritis, Goodpasture's syndrome, granulomatous arteritis, hemarthrosis, hemochromatosis, Henoch-Schonlein purpura, Hepatitis B surface antigen disease, hip dysplasia, Hurler syndrome, hypermobility syndrome, hypersensitivity vasculitis, hypertrophic osteoarthropathy, immune complex disease, impingement syndrome, Jaccoud's arthropathy, juvenile ankylosing spondylitis, juvenile dermatomyositis, juvenile rheumatoid arthritis, Kawasaki disease, Kienbock's disease, Legg-Calve-Perthes disease, Lesch-Nyhan syndrome, linear scleroderma, lipoid dermatoarthritis, Lofgren's syndrome, Lyme disease, malignant synovioma, Marfan's syndrome, medial plica syndrome, metastatic carcinomatous arthritis, mixed connective tissue disease, mixed cryoglobulinemia, mucopolysaccharidosis, multicentric reticulohistiocytosis, multiple epiphyseal dysplasia, mycoplasmal arthritis, myofascial pain syndrome, neonatal lupus, neuropathic arthropathy, nodular panniculitis, ochronosis, olecranon bursitis, Osgood-Schlatter's disease, osteoarthritis, osteochondromatosis, osteogenesis imperfecta, osteomalacia, osteomyelitis, osteonecrosis, osteoporosis, overlap syndrome, pachydermoperiostosis Paget's disease of bone, palindromic rheumatism, patellofemoral pain syndrome, Pellegrini-Stieda syndrome, pigmented villonodular synovitis, piriformis syndrome, plantar fasciitis, polyarteritis nodos, Polymyalgia rheumatic, polymyositis, popliteal cysts, posterior tibial tendinitis, Pott's disease, prepatellar bursitis, prosthetic joint infection, pseudoxanthoma elasticum, psoriatic arthritis, Raynaud's phenomenon, reactive arthritis/Reiter's syndrome, reflex sympathetic dystrophy syndrome, relapsing polychondritis, retrocalcaneal bursitis, rheumatic fever, rheumatoid vasculitis, rotator cuff tendinitis, sacroiliitis, salmonella osteomyelitis, sarcoidosis, saturnine gout, Scheuermann's osteochondritis, scleroderma, septic arthritis, seronegative arthritis, shigella arthritis, shoulder-hand syndrome, sickle cell arthropathy, Sjogren's syndrome, slipped capital femoral epiphysis, spinal stenosis, spondylolysis, staphylococcus arthritis, Stickler syndrome, subacute cutaneous lupus, Sweet's syndrome, Sydenham's chorea, syphilitic arthritis, systemic lupus erythematosus, Takayasu's arteritis, tarsal tunnel syndrome, tennis elbow, Tietse's syndrome, transient osteoporosis, traumatic arthritis, trochanteric bursitis, tuberculosis arthritis, arthritis of Ulcerative colitis, undifferentiated connective tissue syndrome, urticarial vasculitis, viral arthritis, Wegener's granulomatosis, Whipple's disease, Wilson's disease, and yersinial arthritis.

### Claim 13 (depends on 9)

The method of claim 9, further comprising administering an agent selected from the group consisting of a chemotherapeutic agent or an anti-inflammatory agent.

### Claim 14 (depends on 1)

A method of reducing metastatic spread of a cancer cell in a subject comprising administering a compound of claim 1 in a pharmaceutically appropriate formulation to said subject.

### Claim 15 (depends on 1)

A method of reducing growth of a cancer cell in a subject comprising administering a compound of claim 1 in a pharmaceutically appropriate formulation to said subject.

### Claim 16 (depends on 1)

A method of reducing growth of a tumor in a subject comprising administering a compound of claim 1 in a pharmaceutically appropriate formulation to said subject.

### Claim 17 (depends on 1)

A method of inhibiting the in vitro activity of rho protein comprising exposing said rho protein to a composition of claim 1.

### Claim 18 (depends on 17)

The method of claim 17, wherein said rho protein is selected from the group consisting o rhoA and rhoC.

### Claim 19 (depends on 17)

The method of claim 17, wherein said activity is assessed by measuring the expression of a rho-mediated gene.

### Claim 20 (depends on 19)

The method of claim 19, wherein said measurement comprises assessing the level of a rho-mediated gene transcript.

### Claim 21 (depends on 19)

The method of claim 19, wherein said measurement comprises assessing the level of a rho-mediated protein.

### Claim 22 (depends on 19)

The method of claim 19, wherein said measurement comprises assessing the level of activity of a rho-mediated protein.

### Claim 23 (depends on 1)

The composition of claim 1, comprising compound II, wherein T is:
wherein X is (CH2)1, Y is (CH2)1, and Z is (CH2)0.

### Claim 24 (depends on 23)

The composition of claim 23, wherein R1 is a halogen and R2 is a heterocyclic subgroup.

### Claim 25 (depends on 24)

The composition of claim 24, wherein R2 is a furan.

### Claim 26 (depends on 23)

The composition of claim 23, wherein G2 is (C═O)NH.

### Claim 27 (depends on 1)

The composition of claim 1, comprising compound II, wherein T is:
wherein R1 is a halogen and R2 is a heterocyclic subgroup, and wherein said heterocyclic subgroup is a furan;
wherein X is (CH2)1, Y is (CH2)1, and Z is (CH2)0; and
wherein G2 is (C═O)NH.
